Uppsala, Sweden

Ilze Mutule


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 2006-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Mind of Ilze Mutule

Introduction

Ilze Mutule, an accomplished inventor based in Uppsala, Sweden, has made significant contributions in the field of pharmaceuticals. With a keen focus on developing selective compounds that target melanocortin receptors, his work holds promise for treating inflammatory conditions effectively.

Latest Patents

Ilze Mutule holds two notable patents related to melanocortin 1 receptor selective compounds. The first patent encompasses methods of treatment that involve administering a compound characterized by a specific general formula to either patients or healthy individuals. His second patent elaborates on the compound's structure, detailing its high selectivity and affinity for MC1 receptors while ensuring low affinity for other subtypes of melanocortin receptors. This innovation demonstrates effective stimulation or inhibition of cAMP formation in cells expressing MC1 receptors. Furthermore, the patent includes a DNA molecule and a corresponding vector that encodes the compound, a fusion protein, and a pharmaceutical composition that harnesses the compound’s therapeutic potential.

Career Highlights

Ilze Mutule is currently affiliated with Action Pharma A/S, a company dedicated to advancing healthcare through innovative solutions. His dedication to pharmaceutical research has positioned him as a significant player in the development of treatments targeting melanocortin pathways.

Collaborations

During his career, Ilze has collaborated with several talented individuals, including Michael Szardenings and Ruta Muceniece, who have played vital roles in furthering his research initiatives. These collaborations have fostered a productive environment for innovation and discovery.

Conclusion

Ilze Mutule’s work exemplifies the spirit of innovation necessary in advancing medical science. His patents on melanocortin 1 receptor selective compounds are a testament to his creativity and dedication, potentially paving the way for new therapeutic approaches to combat inflammatory conditions. The collaborative efforts with his colleagues further highlight the importance of teamwork in achieving groundbreaking advancements in the pharmaceutical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…